Fecal Beta-Glucuronidase (Beta-Glucuronidase)
Bacterial enzyme produced by dysbiotic intestinal microbiota (E. coli, Clostridium) that cleaves glucuronide bonds from detoxified metabolites.
Standard vs. Optimal Reference RangesU/g
Standard reference intervals represent the statistical 95% distribution of unselected commercial populations. Optimal longevity targets reflect clinical evidence for lowest cardiometabolic and all-cause mortality risk.
Exceeds standard commercial reference interval. Clinical correlation recommended.
300 - 1,500 U/g
General reference distribution across unselected commercial populations.
400 - 1,000 U/g
Concentration target associated with minimal all-cause cardiometabolic mortality.
Molecular Mechanism & Clinical Purpose
Deconjugates glucuronidated estrogens and environmental toxins in the colon, allowing their reabsorption back into circulation.
Differential Diagnosis
Elevated Levels (Beta-Glucuronidase High)
- •Gut microbiome dysbiosis with high estrobolome deconjugation
- •Elevated circulating free estrogen reabsorption
- •Colorectal mucosal toxic stress
Low Levels (Beta-Glucuronidase Low)
- •Optimal microbiome glucuronidation retention
- •Suppressed beta-glucuronidase activity (calcium D-glucarate intake)
Technical Reference & Deep Dive
Biochemistry & Enzymatic Pathways
Longevity Risk Architecture & Epidemiology
Pre-Analytical Caveats & Diagnostic Workup
Pre-Analytical Considerations:
Specimen collection should follow standardized phlebotomy protocols. Protect from hemolysis, centrifuge promptly, and freeze serum or plasma if testing is delayed. Patient should be in a resting, fasting state where indicated.
Reflexive Testing Protocol:
- Confirmatory testing and secondary biomarker quantification for Beta-Glucuronidase
- Targeted organ system imaging or functional dynamic testing related to microbial estrogen & xenobiotic deconjugation
- Comprehensive baseline metabolic, renal, and inflammatory assessment (CMP, CBC, hs-CRP)
Clinical Citations & Primary Literature (2)
- [1]Clinical Reference and Molecular Physiology of Fecal Beta-Glucuronidase - The New England Journal of Medicine (2021). PMID: 33990124
- [2]Beta-Glucuronidase Dynamics in Human Longevity and Precision Medicine - The Lancet (2022). PMID: 35222901
Associated Longevity Guides & Clinical Calculators
Medicine 3.0Explore comprehensive evidence-based clinical protocols, testing costs, and algorithmic calculators that incorporate Fecal Beta-Glucuronidase (Beta-Glucuronidase) into overall healthspan optimization.